A 42-year-old woman with known HIV infection (CD4 count 85 cells/μL) is diagnosed with sputum-smear-positive pulmonary TB. She has no prior TB or antiretroviral therapy. After 2 weeks of anti-TB therapy (HRZE), she develops fever, worsening cough, and new nodular infiltrates on chest X-ray. Sputum smear remains positive. What is the most appropriate next step?

Explanation

## Clinical Scenario Analysis This is a case of **HIV-TB coinfection with severe immunosuppression (CD4 <100)** presenting with **apparent clinical worsening** after 2 weeks of anti-TB therapy. ## Key Differential Diagnosis | Diagnosis | Likelihood | Clue | |-----------|-----------|------| | **TB-IRIS** (Immune Reconstitution Inflammatory Syndrome) | High | New/worsening infiltrates after starting TB therapy in very low CD4; improves with ART | | **Treatment failure / MDR-TB** | Lower (early to assess) | Only 2 weeks into therapy; sputum may remain positive initially | | **Opportunistic infection** | Possible | CD4 <100; but would expect other systemic signs | | **Inadequate drug absorption** | Possible | Diarrhea, malabsorption in HIV | ## Why Sputum Remains Positive at 2 Weeks? **Key Point:** Sputum smear positivity can persist for 2–8 weeks even in drug-susceptible TB with adequate therapy. This is **not** evidence of treatment failure. Sputum conversion is gradual. ## Management Approach 1. **Do NOT switch to second-line drugs yet.** This is premature at 2 weeks and risks unnecessary exposure to toxic agents. 2. **Do NOT discontinue TB therapy.** TB drugs are working; worsening is likely immune-mediated (TB-IRIS). 3. **Send sputum for culture and DST** to rule out MDR-TB and guide future therapy if needed. 4. **Continue HRZE and initiate ART immediately.** ART restores CD4 count, which paradoxically may worsen inflammation initially (TB-IRIS) but ultimately improves outcomes. ## TB-IRIS Pathophysiology - Occurs 1–3 months after starting ART in TB-HIV coinfection. - Immune system recovers and mounts exaggerated inflammatory response to TB antigens. - Managed with continued TB therapy + ART + NSAIDs ± corticosteroids (if severe). - **NOT** managed by stopping TB drugs or switching to second-line therapy. **High-Yield:** In HIV-TB coinfection, **worsening on early TB therapy + very low CD4 = TB-IRIS until proven otherwise**. The correct response is to continue TB drugs, start ART, and send cultures for surveillance—not to escalate to second-line therapy. ## Timing of ART - CD4 <50: Start ART within 2 weeks of TB therapy initiation. - CD4 50–200: Start ART within 2 weeks (preferably) to 8 weeks. - CD4 >200: Can delay ART slightly but still recommended early. This patient (CD4 85) should start ART immediately.